Beam Therapeutics Reports Progress Across Ex Vivo and In
First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle Cell Disease in the Second Half of 2022 BEAM-301...
Source: globenewswire.com
Stay updated with breaking news from Fourth Development Candidate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle Cell Disease in the Second Half of 2022 BEAM-301...
First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle Cell Disease in the Second Half of 2022 BEAM